Dr. Choy specializes in the treatment of bone and soft tissue sarcomas, chordomas, desmoid tumors, and giant cell tumors at the MGH Cancer Center. Sarcomas are rare malignant tumors derived from connective tissue. Although a substantial group of sarcomas are characterized by a defined chromosomal translocations, the molecular basis for most subtypes of sarcomas is unknown. In collaboration with other investigators at The Massachusetts General Hospital, The Dana-Farber Cancer Institute, and The Broad Institute, he utilizes high-throughput genotyping technology to understand the molecular basis of sarcomas in order to gain insight into novel therapeutic options for patients who would otherwise have no treatment alternatives. In addition to this translational approach, his clinical research team collaborates closely with the sarcoma team at Dana-Farber in testing novel agents in a patient population in a phase I, II, or III setting. His team is currently enrolling patients onto clinical trials perturbing the IGF1R, mTor, src, DR5, VEGF, c-met, and hsp-90 pathways.
Biography Updated on 21 May 2012